Krilogy Financial LLC boosted its position in Centene Corporation (NYSE:CNC – Free Report) by 66.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 87,997 shares of the company’s stock after purchasing an additional 35,211 shares during the quarter. Krilogy Financial LLC’s holdings in Centene were worth $3,621,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of the business. UniSuper Management Pty Ltd grew its holdings in Centene by 66.0% in the third quarter. UniSuper Management Pty Ltd now owns 85,232 shares of the company’s stock worth $3,041,000 after purchasing an additional 33,875 shares during the period. Oracle Investment Management Inc. purchased a new position in shares of Centene during the third quarter valued at approximately $3,936,000. Packer & Co Ltd bought a new stake in shares of Centene in the 3rd quarter worth approximately $50,487,000. ARGA Investment Management LP purchased a new stake in shares of Centene in the 3rd quarter worth approximately $21,485,000. Finally, First Citizens Bank & Trust Co. grew its stake in shares of Centene by 122.5% in the 3rd quarter. First Citizens Bank & Trust Co. now owns 223,157 shares of the company’s stock worth $7,962,000 after buying an additional 122,870 shares during the last quarter. Institutional investors own 93.63% of the company’s stock.
Centene Stock Down 0.2%
CNC stock opened at $38.11 on Monday. The stock has a market capitalization of $18.74 billion, a P/E ratio of -2.80, a P/E/G ratio of 0.85 and a beta of 0.59. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.10 and a quick ratio of 1.10. Centene Corporation has a 1-year low of $25.08 and a 1-year high of $64.15. The business has a fifty day moving average price of $38.23 and a 200-day moving average price of $39.04.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on the company. Cantor Fitzgerald reiterated a “neutral” rating and set a $41.00 price objective on shares of Centene in a research note on Monday, February 9th. Wells Fargo & Company set a $44.00 price target on Centene and gave the company an “equal weight” rating in a report on Wednesday, February 18th. Mizuho set a $41.00 price target on Centene and gave the stock a “neutral” rating in a research report on Tuesday, March 10th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Centene from $32.00 to $39.00 and gave the company a “hold” rating in a research report on Tuesday, February 10th. Finally, Robert W. Baird raised their price objective on shares of Centene from $36.00 to $37.00 and gave the company a “neutral” rating in a research note on Wednesday, April 15th. Three investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, Centene currently has an average rating of “Hold” and a consensus price target of $41.88.
Get Our Latest Stock Analysis on CNC
Centene Profile
Centene Corporation (NYSE: CNC) is a diversified, multi-national healthcare enterprise that specializes in providing services to government-sponsored and national health programs. The company primarily acts as a managed care organization, delivering healthcare coverage and administering benefits for Medicaid, the Children’s Health Insurance Program (CHIP), Medicare Advantage, and individual marketplace plans. Centene also contracts with federal and state agencies to manage specialty care programs and community-based services for vulnerable populations.
Centene’s offerings extend beyond traditional insurance to include a range of specialty and support services.
Featured Articles
Want to see what other hedge funds are holding CNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centene Corporation (NYSE:CNC – Free Report).
Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.
